Key result
Beta-1 selective beta-blockers demonstrate high efficacy and safety in patients with chronic heart failure, with heart rate reduction being the primary mechanism for improving clinical outcomes.
Why the study?
Does beta-blocker therapy improve outcomes in patients with chronic heart failure?
Does beta-blocker therapy improve outcomes in patients with chronic heart failure?
The correct choice of beta-blockers and achieving target heart rate reduction significantly increases treatment effectiveness and improves prognosis in chronic heart failure.
May support beta-1 selective beta-blockers in chronic HF; leaves open optimal heart rate targets for prospective trials.
Objective – review current data on the use of beta-blockers (BB) in chronic heart failure (CHF).Materials and methods. This article discusses beneficial effects of BB administration in CHF patients. It has been demonstrated that decrease in heart rate underlies clinical efficacy of BB therapy in patients with chronic heart failure. We reviewed the question of the necessity to achieve target doses of BB in the treatment of CHF patients. It has been shown that administration of BB in patients with chronic heart failure and reduced left ventricular ejection fraction increase pumping function of heart, and thus reduce the number of hospitalizations for decompensated heart failure, reducing the risk of total and sudden mortality. We demonstrated substantial advantages of β1-selective BB over nonselective ones with respect to their impact on hemodynamics, metabolic processes, rheological parameters of blood and bronchi. We also considered therapeutic tactics in case of BB administration in CHF patients.Results. Based on the data of the current studies we proved high efficiency and safety of β1-selective BBs in CHF patients.Conclusion. Correct choice of BB in patients with CHF and decrease in heart rate during the treatment can significantly increase an effectiveness of the treatment.
No takes yet. Share an insight, caveat, or question.
Шостак et al. (2016) conducted a review in Chronic heart failure. Beta-blockers was evaluated. Beta-1 selective beta-blockers demonstrate high efficacy and safety in patients with chronic heart failure, with heart rate reduction being the primary mechanism for improving clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: